ConductScience.org, home

Paper630199

Prednimustine therapy for advanced prostatic cancer.

Catane R and 4 others. Br J Urol, 1978. Cited by 26 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Prednimustine therapy for advanced prostatic cancer. Papers, record 630199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/630199

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prednimustine therapy for advanced prostatic cancer.
PubMed
Journal
Br J Urol
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.81
iCite
Revised in PubMed
2019-07-19
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Catane RR
2Kaufman JHJ H
3Madajewicz SS
4Mittelman AA
5Murphy GPG P

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ChlorambucilMajor topic
PrednisoloneMajor topic
Prostatic NeoplasmsMajor topic
Adrenal Glands
Aged
Chemical Phenomena
Chemistry
Drug Combinations
Humans
Male
Middle Aged

Source PubMed

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
15,570,307Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.Br J Cancer2005https://conductscience.org/library/papers/15570307PubMed
7,679,331Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/7679331PubMed
6,871,484Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.Breast Cancer Res Treat1983https://conductscience.org/library/papers/6871484PubMed
6,640,823Disposition of orally administered 14C-prednimustine in cancer patients.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6640823PubMed
6,254,684Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6254684PubMed
1,537,076Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.Cancer Chemother Pharmacol1992https://conductscience.org/library/papers/1537076PubMed
394,873Prednimustine in adult acute myeloid leukaemia.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/394873PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/630199

GET https://conductscience.org/api/papers/v1/630199/authors